News

The collaboration will explore the use of EyeGate’s iontophoresis technology, which is currently being studied in a Phase III trial with an anti-inflammatory product (EGP-437), to deliver RXi’s

Additionally, a pharmacokinetic study was presented, which investigated linagliptin in a special patient population with different degrees of renal impairment. Linagliptin belongs to the new class of DPP-4

RapID, developed in collaboration with ZyGem as a Lockheed Martin Technology innovation initiative, leverages the latest in microfluidic research and development to accelerate the DNA identification process essentially

Parexel will assist Lilly in bringing efficiencies to its clinical research studies to help meet Lilly’s development and commercialisation goals. The collaboration will allow Lilly to focus on

As per the terms of the agreement, Rapid Micro Biosystems is expected to receive $2.2m in the first contract year and up to an additional $4.5m in two

As per the terms of the agreement, Sanofi-aventis will have access to Belfer’s cancer target identification and validation platform, and translational medicine capabilities. Belfer has licensed Sanofi-aventis an

Phase II clinical study was a double-blind, randomised, placebo-controlled, parallel-group trial designed to evaluate Sativex in patients with MS and overactive bladder (OAB) that was not responding adequately

Mitsui has been a solution provider to pharma firms with services ranging from supplying raw materials, chemical intermediates and APIs to support management of manufacturing as well as

Microbia claimed that it has developed a technology platform that enables it to produce high-quality, natural carotenoids (including ß-carotene and canthaxanthin), nutritional products and other specialty materials and